Oxford BioTherapeutics brings Phase Ib trial with OBT-076 to Europe
Oxford BioTherapeutics expanded its US-based trial investigating OBT-076 as monotherapy and combination treatment to European sites.
Excerpt from the Press Release:
UK-based oncology company Oxford BioTherapeutics has initiated a Phase Ib trial evaluating OBT-076 in patients with solid tumours at a European site.
The company dosed the first patient with its CD205 targeting antibody-drug conjugate (ADC).
The trial is investigating OBT-076 in combination with Agenus’ anti-PD1 checkpoint inhibitor (CPI) balstilimab. The combination trial will enrol patients who are CPI-naïve and resistant patients with advanced solid tumours, including lung, gastric and ovarian cancers.
Oxford BioTherapeutics announced its collaboration with Agenus in May 2022. Under the agreement, Oxford BioTherapeutics is sponsoring the trial and is responsible for operational execution while Agenus is providing drug supply and scientific support.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?